The Molecular Cytogenetics Market Size is valued at USD 3.13 Bn in 2023 and is predicted to reach USD 6.72 Bn by the year 2031 at an 10.4% CAGR during the forecast period for 2024-2031.
Molecular cytogenetics merges molecular biology with cytogenetic techniques to study chromosomes and their abnormalities, which is important in disease diagnosis caused by genetic anomalies or cancer. Advanced methods like Fluorescence In Situ Hybridization (FISH) and Comparative Genomic Hybridization (CGH) are used in molecular cytogenetics. FISH is applied for visualizing specific DNA sequences on chromosomes, thus helping detect chromosomal anomalies such as deletions and translocations, especially in the case of cancerous cells. CGH compares the genomic contents of a test sample and a reference to highlight gains or losses within chromosomal regions, giving insight into numerous genetic disorders.
Molecular cytogenetics is applied in both clinical diagnostics and prenatal diagnosis besides research in cancers. The principal application of diagnosing genetic disorders, such as Down's syndrome, or identifying mutations associated with cancers may result in targeted therapies being developed. The ever-increasing incidence of genetic disorders and cancers is one of the prime drivers of this molecular cytogenetics market. Improving awareness and diagnosis rates coupled with increasing demands for sophisticated and high-precision diagnostic tools are further fueled by ongoing research and technology, which is bettering the accessibility and effectiveness.
The molecular cytogenetics market is segmented by product, technique, application, and end user. By product the market is segmented into kits & reagents, instruments, consumables, software & services. By kits & reagents it is sub segmented into testing kits, probes, fluorescent affinity reagents, other kits & reagents. By Technique market is comparative genomic hybridization, fluorescence in-situ hybridization, chromogenic in-situ hybridization, other techniques. Comparative genomic hybridization is sub segmented into array-based comparative genomic hybridization, standard comparative genomic hybridization. By application market is categorized into genetic disorders, cancer, personalized medicine, other applications. By end user the market is categorized into clinical & research laboratories, academic research institutes, pharmaceutical & biotechnology companies, and other end users.
The Kits & Reagents segment is leading the molecular cytogenetics market, with its greatest importance in diagnostics and research. High demand for these kits, probes, and fluorescent affinity reagents is required in clinical labs as well as research institutes in detecting chromosomal anomalies and genetic diseases, thereby fueling the demand. Such products are also being increasingly used for diagnosis and planning of treatments because of the increasing incidence of cancers and genetic disorders. The same productivity and efficiency of these products combined with growth in personalized medicine are going to continue to make the segment hold sway over the market.
The Array-Based Comparative Genomic Hybridization (aCGH) segment is experiencing rapid growth in the molecular cytogenetics market due to its high resolution and sensitivity, allowing for the detection of submicroscopic chromosomal alterations like deletions, duplications, and copy number variations (CNVs) often missed by traditional methods. The simplified process-the elimination of the need for cell culture and the ability to directly analyze DNA from tissue samples-advances testing, increases accessibility in the clinical lab, and improves the process. Advances that could be made were next-generation sequence and high-density arrays, which put aCGH on a faster track to higher accuracy and fully genomic analyses. This means that as aCGH continues to be integrated into clinical diagnostics, especially in oncology and prenatal testing, it now replaces the older conventional techniques such as FISH-based due to its efficiency and value in personalized medicine.
Advanced healthcare infrastructure and a huge investment in R&D make North America a prominent region for the molecular cytogenetics market. The healthcare system is strong; hence, it has the space to quickly adopt new technologies both in diagnostics and research. Innovation activities are conducted by companies such as Agilent Technologies, Illumina, and Thermo Fisher Scientific, who also make a large R&D investment. But it is the rising prevalence of genetic disorders as well as chronic diseases such as cancer and sickle cell disease-that affect about 70,000 to 100,000 Americans-driving the molecular cytogenetics market. Government efforts in the form of campaigns advocating genetic testing and offering grants to engage in genomic research also propel the market with widened clinical use of such advanced diagnostic methods.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 3.13 Bn |
|
Revenue Forecast In 2031 |
USD 6.72 Bn |
|
Growth Rate CAGR |
CAGR of 10.4% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Technique, Application, End User, and By Region |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; Southeast Asia |
|
Competitive Landscape |
F. Hoffmann-La Roche Ltd., Danaher Corporation, Agilent Technologies, Inc., Abbott Laboratories, Thermo Fisher Scientific, Inc., Illumina Inc., Revvity, Pacific Biosciences, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Genedx, Oncocyte Corporation, Bioview, Oxford Gene Technology Ip Limited (Part of Sysmex), Applied Spectral Imaging, Inc., Cytotest Inc., Kromatid, Inc., Genial Genetic Solutions Ltd., Cytognomix, Inc., Metasystems, Scigene, Biomodal, Biocare Medical, Biodot, Oncodna |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Molecular Cytogenetics Market Snapshot
Chapter 4. Global Molecular Cytogenetics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2031
4.8. Global Molecular Cytogenetics Market Penetration & Growth Prospect Mapping (US$ Mn), 2023-2031
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.10. Use/impact of AI on Molecular Cytogenetics Industry Trends
Chapter 5. Molecular Cytogenetics Market Segmentation 1: By Product, Estimates & Trend Analysis
5.1. Market Share by Product, 2023 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Product:
5.2.1. Kits & Reagents
5.2.1.1. Testing Kits
5.2.1.2. Probes
5.2.1.3. Fluorescent Affinity Reagents
5.2.1.4. Other Kits & Reagents
5.2.2. Instruments
5.2.3. Consumables
5.2.4. Software & Services
Chapter 6. Molecular Cytogenetics Market Segmentation 2: By Technique, Estimates & Trend Analysis
6.1. Market Share by Technique, 2023 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Technique:
6.2.1. Comparative Genomic Hybridization
6.2.1.1. Array-Based Comparative Genomic Hybridization
6.2.1.2. Standard Comparative Genomic Hybridization
6.2.2. Fluorescence In-Situ Hybridization
6.2.3. Chromogenic In-Situ Hybridization
6.2.4. Other Techniques
Chapter 7. Molecular Cytogenetics Market Segmentation 3: By Application, Estimates & Trend Analysis
7.1. Market Share by Application, 2023 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following Application:
7.2.1. Genetic Disorders
7.2.2. Cancer
7.2.3. Personalized Medicine
7.2.4. Other Applications
Chapter 8. Molecular Cytogenetics Market Segmentation 4: By End-User, Estimates & Trend Analysis
8.1. Market Share by End-User, 2023 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following End-User:
8.2.1. Clinical & Research Laboratories
8.2.2. Academic Research Institutes
8.2.3. Pharmaceutical & Biotechnology Companies
8.2.4. Other End Users
Chapter 9. Molecular Cytogenetics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global Molecular Cytogenetics Market, Regional Snapshot 2023 & 2031
9.2. North America
9.2.1. North America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.2.3. North America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Technique, 2024-2031
9.2.4. North America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.2.5. North America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
9.3. Europe
9.3.1. Europe Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.3.3. Europe Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Technique, 2024-2031
9.3.4. Europe Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.3.5. Europe Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
9.4. Asia Pacific
9.4.1. Asia Pacific Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.4.3. Asia Pacific Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Technique, 2024-2031
9.4.4. Asia Pacific Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts By Application, 2024-2031
9.4.5. Asia Pacific Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
9.5. Latin America
9.5.1. Latin America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2031
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.5.3. Latin America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Technique, 2024-2031
9.5.4. Latin America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.5.5. Latin America Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
9.6. Middle East & Africa
9.6.1. Middle East & Africa Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2031
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2031
9.6.3. Middle East & Africa Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Technique, 2024-2031
9.6.4. Middle East & Africa Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by Application, 2024-2031
9.6.5. Middle East & Africa Molecular Cytogenetics Market Revenue (US$ Million) Estimates and Forecasts by End-User, 2024-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Dentsply Sirona, Inc.
10.2.1.1. Business Overview
10.2.1.2. Key Product/Service Offerings
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. F. Hoffmann-La Roche Ltd.
10.2.3. Danaher Corporation
10.2.4. Agilent Technologies, Inc.
10.2.5. Abbott Laboratories
10.2.6. Thermo Fisher Scientific, Inc.
10.2.7. Illumina Inc.
10.2.8. Revvity
10.2.9. Pacific Biosciences
10.2.10. Bio-Rad Laboratories, Inc.
10.2.11. Bio-Techne Corporation
10.2.12. Genedx
10.2.13. Oncocyte Corporation
10.2.14. Bioview
10.2.15. Other Prominent Players
10.2.15.1. Oxford Gene Technology Ip Limited (Part of Sysmex)
10.2.15.2. Applied Spectral Imaging, Inc.
10.2.15.3. Cytotest Inc.
10.2.15.4. Chromatids, Inc.
10.2.15.5. Genial Genetic Solutions Ltd.
10.2.15.6. Cytognomix, Inc.
10.2.15.7. Metasystems
10.2.15.8. Scigene
10.2.15.9. Biomodal
10.2.15.10. Biocare Medical
10.2.15.11. Biodot
10.2.15.12. Oncodna
Molecular Cytogenetics Market by Product -
Molecular Cytogenetics Market by Technique -
Molecular Cytogenetics Market by Application -
Molecular Cytogenetics Market by End User -
Molecular Cytogenetics Market by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
